Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults

Osmotica (OSMT) PT Raised to $12 at RBC Capital After Upneeq Approval

July 9, 2020 1:03 PM EDT

RBC Capital analyst Randall Stanicky raised the price target on Osmotica (NASDAQ: OSMT) to $12.00 (from $10.00) while maintaining an Outperform rating.

Upneeq approval sets up the next leg of "specialty" growth... More